Rosiglitazone decreases blood pressure and renal injury in a female mouse model of systemic lupus erythematosus
about
PPARγ and the Innate Immune System Mediate the Resolution of InflammationPreclinical lupusCardiovascular disease in lupus: insights and updatesAutoimmune kidney disease and impaired engulfment of apoptotic cells in mice with macrophage peroxisome proliferator-activated receptor gamma or retinoid X receptor alpha deficiency.Sexual dimorphism in the blood pressure response to angiotensin II in mice after angiotensin-converting enzyme blockade.Mouse models of the metabolic syndrome.Can estrogens promote hypertension during systemic lupus erythematosus?Tumor necrosis factor-alpha antagonist etanercept decreases blood pressure and protects the kidney in a mouse model of systemic lupus erythematosusImpact of early life ovariectomy on blood pressure and body composition in a female mouse model of systemic lupus erythematosusThe immunological basis of hypertensionPreventing autoimmunity protects against the development of hypertension and renal injury.Estrogen in cardiovascular disease during systemic lupus erythematosus17β-Estradiol protects against the progression of hypertension during adulthood in a mouse model of systemic lupus erythematosusBlood pressure in a hypertensive mouse model of SLE is not salt-sensitive.Blood pressure and renal hemodynamic responses to acute angiotensin II infusion are enhanced in a female mouse model of systemic lupus erythematosusDeletion of PPAR-γ in immune cells enhances susceptibility to antiglomerular basement membrane diseaseThe PPAR-γ antagonist GW9662 elicits differentiation of M2c-like cells and upregulation of the MerTK/Gas6 axis: a key role for PPAR-γ in human macrophage polarizationProtective effects of PPARγ agonist in acute nephrotic syndrome.Nephropathy in Pparg-null mice highlights PPARγ systemic activities in metabolism and in the immune system.Oxidative stress promotes hypertension and albuminuria during the autoimmune disease systemic lupus erythematosus.Hypertension in an experimental model of systemic lupus erythematosus occurs independently of the renal nerves.Differential expression of functional Fc-receptors and additional immune complex receptors on mouse kidney cellsImmune and inflammatory role in renal disease.Cardiovascular risk in rheumatoid arthritis and systemic autoimmune rheumatic disorders: a suggested model of preventive strategy.Understanding mechanisms of hypertension in systemic lupus erythematosus.Anti-CD3 antibody therapy attenuates the progression of hypertension in female mice with systemic lupus erythematosus.Immunosuppression With Mycophenolate Mofetil Attenuates Hypertension in an Experimental Model of Autoimmune DiseaseImmunometabolism in systemic lupus erythematosus.Role of the Immune System in Hypertension.PPARγ expression is increased in systemic lupus erythematosus patients and represses CD40/CD40L signaling pathway.Inhibitory effects of peroxisome proliferator-activated receptor γ agonists on collagen IV production in podocytes.
P2860
Q26771755-7317E0E5-634A-40EB-A7D8-C8234AC0960DQ26863306-2A3134A3-8E33-457F-AD26-34A96B482B81Q27016554-0A1DB05D-A5AB-4600-967B-DD6237F494D0Q33683897-7E795D60-91F9-4EBD-8506-BA6F3AA65282Q33690864-BB8AB6DD-2525-4DC3-9B64-8CEA7602C43FQ33849244-800D959D-E596-41D7-8B90-1B7DC5FD0DCDQ33961468-0565AB00-D554-4CCF-B649-F91628563E5EQ34339359-E08A2566-F82D-4F9E-8DBD-24CFFA754B1FQ34356411-FE08691B-CF0E-459D-834F-8A0EA2DD66EAQ34683745-AF55F621-C75C-4F8A-9D24-5780C14C1C6EQ35159241-F5DAD440-80B1-4D02-84ED-777AB8137270Q35162962-099ACAAD-E29C-4473-A0E8-5ED9BBE8184EQ35194978-0434AA91-3EF7-454B-8A26-352AE92AD236Q35543439-C2118ECC-7333-46E8-A721-9810C01FFD0AQ35543444-4742DF29-7968-46D0-9881-EF912A76C776Q35557407-F61EC4CB-617D-4C52-9825-99A3D27E3A31Q35600280-AFAFC724-F8CC-4CE2-87BC-B12349EC491CQ35747241-C141AA0F-7CF0-48EB-839F-7B550F5E8827Q36275483-76081605-655B-431C-B2C9-7D7728D738C6Q36932669-A3A69B4F-34DF-4EDA-BB91-25FB05B91A73Q37234995-D2476C7B-2939-4C78-BD1C-D7E247BDE45DQ37237914-C3C1FADE-14C2-41A0-96A6-BBA7958D789DQ37243199-1029D0EF-24AF-447C-801F-1982722A43D8Q37829385-E808E4BC-CE93-472E-B02B-69A4E51E06DCQ38777852-F2F84058-6C33-49CC-B153-F3B92D21F307Q38841726-2F4C062A-991A-482C-B007-053CA37F22EFQ38938727-7D0E7E6E-0F3B-4010-A884-9E7948674891Q39209701-287A6284-D7AA-41D3-9B00-91CEF1A0DC0AQ39342382-498BC2D3-19A6-4742-B696-E5C81D24E0F7Q39574464-848DE802-7669-4423-B7AA-406BC81B0498Q41004141-823BF440-A031-4C1B-BA5B-B972B2C8ACC0
P2860
Rosiglitazone decreases blood pressure and renal injury in a female mouse model of systemic lupus erythematosus
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 04 February 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Rosiglitazone decreases blood ...... f systemic lupus erythematosus
@en
Rosiglitazone decreases blood ...... systemic lupus erythematosus.
@nl
type
label
Rosiglitazone decreases blood ...... f systemic lupus erythematosus
@en
Rosiglitazone decreases blood ...... systemic lupus erythematosus.
@nl
prefLabel
Rosiglitazone decreases blood ...... f systemic lupus erythematosus
@en
Rosiglitazone decreases blood ...... systemic lupus erythematosus.
@nl
P2093
P2860
P1476
Rosiglitazone decreases blood ...... f systemic lupus erythematosus
@en
P2093
Allison V Jones
Christine Maric
Gerald R McLemore
Jane F Reckelhoff
Julio C Sartori-Valinotti
Lorraine C Racusen
Marcia Venegas-Pont
Michael J Ryan
Porter H Glover
P2860
P304
P356
10.1152/AJPREGU.90992.2008
P577
2009-02-04T00:00:00Z